Asad Haider
Stock Analyst at Goldman Sachs
(4.59)
# 834
Out of 4,486 analysts
113
Total ratings
87.5%
Success rate
25.7%
Average return
Main Sectors:
Stocks Rated by Asad Haider
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PFE Pfizer | Maintained: Hold | $26 | $24.07 | +8.02% | 19 | Jun 23, 2026 | |
| ABBV AbbVie | Maintained: Hold | $244 | $254.65 | -4.18% | 7 | Jun 22, 2026 | |
| JNJ Johnson & Johnson | Rated: Buy | $275 | $267.24 | +2.90% | 19 | Jun 11, 2026 | |
| LLY Eli Lilly and Company | Rated: Buy | $1,283 | $1,235.56 | +3.84% | 22 | Jun 8, 2026 | |
| MRK Merck & Co. | Maintained: Buy | $137 | $128.86 | +6.32% | 17 | Jun 2, 2026 | |
| BMY Bristol-Myers Squibb Company | Maintained: Hold | $61 | $57.97 | +5.23% | 10 | May 28, 2026 | |
| RPRX Royalty Pharma | Rated: Buy | $51 → $59 | $57.80 | +2.08% | 3 | May 7, 2026 | |
| NAMS NewAmsterdam Pharma Company | Maintained: Hold | $37 → $38 | $36.99 | +2.73% | 4 | May 7, 2026 | |
| INVA Innoviva | Maintained: Sell | $17 → $18 | $22.25 | -19.10% | 2 | May 6, 2026 | |
| BNTX BioNTech SE | Maintained: Buy | $132 → $133 | $94.29 | +41.05% | 5 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $38 → $67 | $60.67 | +10.43% | 2 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $270 | $368.10 | n/a | 1 | Dec 16, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $66 | $12.19 | n/a | 1 | Dec 16, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $168 | $168.68 | n/a | 1 | Dec 14, 2018 |
Pfizer
Jun 23, 2026
Maintained: Hold
Price Target: $26
Current: $24.07
Upside: +8.02%
AbbVie
Jun 22, 2026
Maintained: Hold
Price Target: $244
Current: $254.65
Upside: -4.18%
Johnson & Johnson
Jun 11, 2026
Rated: Buy
Price Target: $275
Current: $267.24
Upside: +2.90%
Eli Lilly and Company
Jun 8, 2026
Rated: Buy
Price Target: $1,283
Current: $1,235.56
Upside: +3.84%
Merck & Co.
Jun 2, 2026
Maintained: Buy
Price Target: $137
Current: $128.86
Upside: +6.32%
Bristol-Myers Squibb Company
May 28, 2026
Maintained: Hold
Price Target: $61
Current: $57.97
Upside: +5.23%
Royalty Pharma
May 7, 2026
Rated: Buy
Price Target: $51 → $59
Current: $57.80
Upside: +2.08%
NewAmsterdam Pharma Company
May 7, 2026
Maintained: Hold
Price Target: $37 → $38
Current: $36.99
Upside: +2.73%
Innoviva
May 6, 2026
Maintained: Sell
Price Target: $17 → $18
Current: $22.25
Upside: -19.10%
BioNTech SE
May 5, 2026
Maintained: Buy
Price Target: $132 → $133
Current: $94.29
Upside: +41.05%
Feb 26, 2026
Maintained: Hold
Price Target: $38 → $67
Current: $60.67
Upside: +10.43%
Dec 16, 2019
Upgraded: Buy
Price Target: $270
Current: $368.10
Upside: n/a
Dec 16, 2019
Upgraded: Buy
Price Target: $66
Current: $12.19
Upside: n/a
Dec 14, 2018
Maintained: Buy
Price Target: $168
Current: $168.68
Upside: n/a